Belzutifan治疗von Hippel-Lindau病相关肾细胞癌及其他肿瘤(LITESPARK-004):单臂2期研究50个月随访
LITESPARK-004是一项单臂2期研究,在11个中心纳入61例von Hippel-Lindau病相关肾细胞癌患者,口服Belzutifan 120 mg每日一次。中位随访49.9个月,客观缓解率为67%(95% CI 54-79),其中完全缓解11%、部分缓解56%。更新结果支持Belzutifan用于von Hippel-Lindau病相关肾细胞癌的系统治疗。
要点
- 中位随访49.9个月,肾细胞癌客观缓解率67%(95% CI 54-79),完全缓解11%、部分缓解56%。
- 3级治疗相关不良事件发生于11例(18%),无4级或5级治疗相关不良事件。
- 4例(7%)发生严重治疗相关不良事件,分别为贫血、尿路感染、颅内出血和缺氧各1例。
核心结论
- 更新结果支持将Belzutifan用作von Hippel-Lindau病相关肾细胞癌的系统治疗。
研究设计与样本
- 单臂2期研究,在丹麦、法国、英国和美国的11个中心入组。
- 2018年5月31日至2019年3月29日共入组61例成人患者,截至2023年4月3日36例(59%)仍在继续治疗。
- 入组条件为基于胚系VHL改变的von Hippel-Lindau病诊断、至少一个可测量肾细胞癌肿瘤、无需要立即手术的超过3 cm肿瘤、无转移性疾病、无既往系统抗肿瘤治疗、ECOG评分为0或1。
- 口服Belzutifan 120 mg每日一次;主要终点为独立评审委员会按RECIST 1.1评估的von Hippel-Lindau病相关肾细胞癌客观缓解比例,在所有接受至少一剂Belzutifan的参与者中评估。
主要发现
- 全部入组患者中位年龄41.0岁(IQR 29.0-51.0);61例中男性32例(52%)、女性29例(48%);多数为白人(55例;90%)。
- 中位研究随访49.9个月(IQR 48.9-52.2)。
- 61例肾细胞癌患者中41例(67%;95% CI 54-79)达到客观缓解,其中7例(11%)完全缓解、34例(56%)部分缓解。
- 11例(18%)共发生13起3级治疗相关不良事件:贫血7例(11%)、疲乏3例(5%)、尿路感染1例(2%)、缺氧1例(2%)、水疱1例(2%)。
- 无参与者发生4级或5级治疗相关不良事件;4例(7%)发生严重治疗相关不良事件,分别为贫血、尿路感染、颅内出血和缺氧各1例。
临床怎么用
- 原文结论为更新结果支持将Belzutifan用作von Hippel-Lindau病相关肾细胞癌的系统治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypoxia-inducible factor-2α inhibitor belzutifan is approved for von Hippel-Lindau disease-associated renal cell carcinoma, CNS haemangioblastomas, and pancreatic neuroendocrine tumours, based on previously published initial results from the LITESPARK-004 study. Updated results are presented here after a median follow-up of nearly 50 months. METHODS: In this single-arm, phase 2 study, participants were enrolled at 11 centres in Denmark, France, the UK, and the USA. Oral belzutifan 120 mg once daily was given to eligible adults aged 18 years or older with a diagnosis of von Hippel-Lindau disease (based on germline VHL alterations), at least one measurable renal cell carcinoma tumour, no tumour larger than 3 cm that necessitated immediate surgery, no metastatic disease, no previous systemic anticancer treatment, and an Eastern Cooperative Oncology Group performance status score of 0 or 1. The primary endpoint was the proportion of participants with an objective response in von Hippel-Lindau disease-associated renal cell carcinoma per Response Evaluation Criteria in Solid Tumours, version 1.1, determined by an independent review committee, and assessed in all participants who received at least one dose of belzutifan. This ongoing study is no longer recruiting and is registered at ClinicalTrials.gov, NCT03401788. FINDINGS: Between May 31, 2018, and Mar 29, 2019, 61 participants were enrolled; 36 (59%) were continuing treatment as of April 3, 2023. The median age of all enrolled participants was 41·0 years (IQR 29·0-51·0); 32 (52%) of 61 participants were male and 29 (48%) were female; most were White (n=55; 90%). Median study follow-up was 49·9 months (IQR 48·9-52·2). 41 (67%; 95% CI 54-79) of 61 participants with renal cell carcinoma had an objective response; seven (11%) had a complete response and 34 (56%) a partial response. 13 grade 3 treatment-related adverse events occurred in 11 (18%) participants (anaemia: seven [11%]; fatigue: three [5%]; urinary tract infection: one [2%]; hypoxia: one [2%]; and blister: one [2%]). None of the participants had a grade 4 or 5 treatment-related adverse event. Four (7%) participants had serious treatment-related adverse events (one participant each: anaemia, urinary tract infection, intracranial haemorrhage, and hypoxia). INTERPRETATION: Updated results support the use of belzutifan as systemic treatment for von Hippel-Lindau disease-associated renal cell carcinoma. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA; the Intramural Research Program of the National Institutes of Health, National Cancer Institute Center for Cancer Research; and a grant from the National Cancer Institute.
引用
- Srinivasan R, Iliopoulos O, Beckermann KE, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025. PMID: 40228516. doi:10.1016/S1470-2045(25)00099-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。